Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Total Current Liabilities: 2021-2025

  • Abivax's Total Current Liabilities rose 47.68% to $127.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $127.2 million, marking a year-over-year increase of 47.68%. This contributed to the annual value of $100.4 million for FY2024, which is 2.94% up from last year.
  • Abivax's Total Current Liabilities amounted to $127.2 million in Q2 2025, which was up 14.34% from $111.2 million recorded in Q1 2025.
  • Abivax's 5-year Total Current Liabilities high stood at $127.2 million for Q2 2025, and its period low was $36.9 million during Q4 2021.
  • Its 3-year average for Total Current Liabilities is $104.5 million, with a median of $100.4 million in 2024.
  • Data for Abivax's Total Current Liabilities shows a peak YoY soared of 85.85% (in 2023) over the last 5 years.
  • Abivax's Total Current Liabilities (Quarterly) stood at $36.9 million in 2021, then spiked by 42.25% to $52.5 million in 2022, then surged by 85.85% to $97.6 million in 2023, then grew by 2.94% to $100.4 million in 2024, then surged by 47.68% to $127.2 million in 2025.
  • Its Total Current Liabilities stands at $127.2 million for Q2 2025, versus $111.2 million for Q1 2025 and $100.4 million for Q4 2024.